FDA Reasserts Dura Mater Device Status During Interim Preceding GTPs
This article was originally published in The Gray Sheet
Executive Summary
FDA is moving forward with rules establishing human dura mater as a Class II medical device before the agency issues guidelines transitioning the product into the purview of tissue regulation
You may also be interested in...
FDA Completes Human Dura Mater Classification, Undeterred By CJD Threat
FDA will classify human dura mater as a Class II device (with special controls), despite lingering concerns raised by cases of dura mater-transmitted Creutzfeldt Jakob Disease (CJD) abroad
FDA Completes Human Dura Mater Classification, Undeterred By CJD Threat
FDA will classify human dura mater as a Class II device (with special controls), despite lingering concerns raised by cases of dura mater-transmitted Creutzfeldt Jakob Disease (CJD) abroad
Tissue Donor Suitability Criteria To Precede GTPs Under Revised FDA Plan
FDA will revise its plans for new risk-based tissue rulemaking by implementing donor suitability and good tissue practice (GTP) final rules concurrently, the agency says. However, the donor suitability final rule will be published first